Oncology Highlights – 30/07/2018

Notizia - Recent Pharma, Healthcare and Biotech Happenings

First Patient Enrolled in Kaizen Clinical Study...

First Patient Enrolled in Kaizen Clinical Study in Japan  On January 11, 2023, Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional t...

Jan 19, 2023

Pharma News and Updates for Luye Pharma, AstraZeneca, Oramed, Eisai, AbbVie
FDA Approves Luye’s Rykindo; EU Approves AstraZeneca’s Tezspire; Oramed Announces Trial Results of ORMD-0801; Eisai and Biogen File Lecanemab in the EU; AbbVie and Anima Biotech Announce Collaboration; AstraZeneca’s Avillion Receives FDA Approval

FDA Approves Luye Pharma’s Rykindo for Schizophrenia Luye Pharma has received its first FDA approval for Rykindo, an injectable formulation of the antipsychotic risperidone administered every two weeks. Rykindo has been approved by the US Food and Drug Administration for the treatment of schizophrenia as well as...

Find More
MedTech News and Updates for Vivos, Arthrex, Chindex, Glaukos, Zimmer Biomet
Vivos Therapeutics ‘s DNA Oral Appliance for the Treatment of OSA; Arthrex’s TightRope Implant for Pediatric ACL Surgery; Chindex Medical Acquired 10 ViewRay MRIdian Systems; Zimmer Biomet to Acquire Embody; GE HealthCare to buy IMACTIS; Glaukos Announced the iDose TR Exchange Trial

Vivos Therapeutics Received FDA 510(k) Clearance for its Flagship DNA Oral Appliance for the Treatment of Obstructive Sleep Apnea On January 4, 2023, Vivos Therapeutics, Inc., a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mil...

Find More
Latest Pharma News and Updates for Ipsen, Chiesi, Takeda, ACELYRIN, Lantern Pharma
Ipsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL

Ipsen to Acquire Albireo for USD 952 Million Ipsen, a French pharmaceutical company, has offered USD 42 per share for the US biotech Albireo and its rare disease treatment Bylvay, continuing a recent spree of merger and acquisition activity. Albireo, a Boston-based business, is valued at USD 952 million under th...

Find More

More Views & Analysis

MedTech News and Updates for Inspira, Burning Rock, Verana, liberDi, Innova
Inspira and Terumo Signed Strategic Agreement; Cook Medical’s New Bipolar Electrodes Portfolio; Verana Health and Sight Sciences Collaborated on Glaucoma Research; Burning Rock’s OverC Multi-Cancer Detection Blood Test; Innova Vascular’s Thrombectomy System; liberDi’s Digital Dialysis System

Inspira Technologies Signed Strategic OEM Agreement with Terumo Cardiovascular On December 27, 2023, Inspira Technologies, a ground breaking respiratory support technology company, announced that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of...

Find More

Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB
Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi

Gilead Buys Out Rights to Cancer Therapy from Jounce for USD 67 Million Gilead Sciences must have liked what it saw in a two-year-old collaboration with Jounce Therapeutics for CCR8-targeting cancer immunotherapy because the company has just agreed to own the program fully. The drug in question, GS-1811 (formerl...

Find More

MedtTech News
PAVmed-Novosound’s Partnership; J&J Acquires Abiomed; Approval to Sysmex’s Assay Kit to Identify Amyloid Beta (Aβ) Accumulation; SI-BONE Announced FDA Clearance for Expanded Rod Compatibility with the iFuse Bedrock Granite Implant System; EOFlow’s Wearable Insulin Pump ‘EOPatch’; Icecure’s ProSense System, a Cryoablation Therapy

PAVmed Entered into a Partnership with Novosound for Ultrasound Imaging Technology On December 22, 2022, PAVmed Inc., a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, announced that the company has entered into a partnership with...

Find More

Pharma News for Gilead, Roche, AstraZeneca, Genentech, Mirati, Pfizer
Gilead Sciences’ Sunlenca Approval; FDA Approves Roche’s CD20xCD3 Bispecific Antibody Lunsumio; EU Approves AstraZeneca’s Imfinzi Plus Chemo; Pfizer Files Blockbuster Hope Etrasimod for Ulcerative Colitis; FDA Approves Mosunetuzumab for R/F Follicular Lymphoma; FDA Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

FDA Approves Gilead Sciences’ Sunlenca Sunlenca, a Gilead Sciences therapy for people with multidrug-resistant (MDR) HIV infection that only needs to be taken twice a year, has received FDA approval for the second time of asking. Sunlenca, which is based on the HIV capsid inhibitor lenacapavir, is intended to be...

Find More

MedTech News for Abbott, Medtronic, Insightec, Life Spine, Thermo Fisher
Medtronic’s Hugo Robotic-Assisted Surgery System Trial; Insightec’s Pivotal LIBERATE Clinical Trial; FDA Granted EMA for Thermo Fisher Scientific’s Monkeypox Test; Life Spine’s Trulift Lateral Expandable Spacer System & Lateral Pate System; Fujifilm & Inspirata Announces Asset Purchase Agreement; Abbott Launched SCS System for Chronic Pain

Medtronic Announced First Patient Enrolment for Hugo™ Robotic-Assisted Surgery System in US Clinical Trial On December 15, 2022, Medtronic, a global healthcare technology leader, announced that the first patient was enrolled in the Expand URO US clinical trial for the Hugo™ robotic-assisted surgery...

Find More

Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda
Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

AbbVie Secures Fourth FDA Approval for Vraylar AbbVie has received its fourth FDA approval for Vraylar, adding major depressive disorder (MDD) adjunctive therapy to a list that includes schizophrenia and manic and depressive episodes in bipolar disorder. According to AbbVie, the approval makes Vraylar (cariprazi...

Find More

Myocardial infarction (MI), colloquially known as “heart attack” is caused by decreased or compl.....

Find More

A complex genetic condition, Prader-Willi syndrome (PWS) is a result of the loss of the functioning .....

Find More

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More

Over the last months, the world has faced one of the most unexpected challenges in the form of a nov.....

Find More

With worldwide dissemination and now over 9 million cases and nearly 500,000 deaths recorded, the ef.....

Find More

Lyme disease is a vector-borne infectious disease that spreads primarily by the bite of a tick (also.....

Find More